Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Glioma × MK 2206 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 5 Carcinoma, Hepatocellular 3 Triple Negative Breast Neoplasms 2 Rectal Neoplasms 2 Gallbladder Neoplasms 2 Colonic Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Thymoma 1 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Salivary Gland Neoplasms 1 Recurrent Squamous Cell Carcinoma of the Nasopharynx 1 Prostatic Neoplasms 1 Pathologic Complete Response 1 Ovarian Neoplasms 1 Neuroendocrine Tumors 1 Neoplasms 1 Nasopharyngeal Carcinoma 1 Melanoma 1 Lymphoma, Large B-Cell, Diffuse 1 Lung Neoplasms 1 Leukemia, Myelomonocytic, Acute 1 Leukemia, Myeloid, Acute 1 Leukemia, Monocytic, Acute 1 Leukemia, Megakaryoblastic, Acute 1 Leukemia, Erythroblastic, Acute 1 Hemangiosarcoma 1 Glioma 1 Fallopian Tube Neoplasms 1 Endometrial Adenocarcinoma 1

Interventions

Temozolomide 59 Bevacizumab 37 Radiotherapy 19 Magnetic Resonance Spectroscopy 18 Irinotecan 16 Carboplatin 10 Specimen Handling 9 Carmustine 9 olaparib 6 X-Rays 6 Surgical Procedures, Operative 6 Phantoms, Imaging 6 Cyclophosphamide 6 Thalidomide 5 Nuclear Medicine Department, Hospital 5 Nivolumab 5 Biopsy 5 trametinib 4 pembrolizumab 4 Radiation 4 Lomustine 4 Everolimus 4 Cisplatin 4 Aminolevulinic Acid 4 sargramostim 3 poly ICLC 3 palbociclib 3 ivosidenib 3 fluorodopa F 18 3 erdafitinib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01249105 2016-03-10

MK-2206 for Recurrent Malignant Glioma

Dana-Farber Cancer Institute

Phase 2 Withdrawn

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡